Sun Pharma Signs Global Licensing Deal for Cholesterol Drug
What Happened
Sun Pharmaceutical Industries announced a global licensing agreement with US‑based LIB Therapeutics for the cholesterol‑lowering drug Lerodalcibep, a PCSK9 inhibitor. The deal gives Sun Pharma worldwide rights (excluding Japan) to develop and commercialize the drug, which targets bad cholesterol (LDL‑C). The global PCSK9 inhibitor market is estimated at $3.7 billion, with Lerodalcibep positioned as a monthly injectable therapy. Sun Pharma stated the agreement strengthens its specialty portfolio in cardiovascular care.
Key Takeaways
The pact expands Sun Pharma’s presence in the high‑value cardiovascular segment, giving it access to a fast‑growing global market. Lerodalcibep could enhance treatment options for patients with hard‑to‑control cholesterol.